-
J Thorac Oncol: Gender differences in survival in lung cancer patients and the impact of prognostic factors on them
Time of Update: 2022-04-23
Recently, an Australian study was published in the Journal of Thoracic Oncology, mainly based on a large cohort study of the Australian population, to evaluate the impact of gender differences on prognosis in lung cancer patients .
-
BMC Cancer: Hematologic changes in patients with unresectable stage III NSCLC receiving durvalumab maintenance therapy after cCRT
Time of Update: 2022-04-23
Recently, a German team published a study in the journal BMC Cancer, mainly to study the hematological changes of durvalumab maintenance therapy after concurrent chemoradiotherapy (cCRT) in patients with stage III unresectable NSCLC .
-
Announcement of data from a study of pembrolizumab in adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
Time of Update: 2022-04-23
Data from the KEYNOTE-091 interim analysis released this time showed that KEYNOTE-091 met one of the dual primary endpoints of pembrolizumab as post-operative adjuvant therapy for patients with stage IB-IIIA non-small cell lung cancer, compared with placebo , a statistically and clinically significant improvement in DFS in the overall population (regardless of PD-L1 expression levels) .
-
Am J Clin Nutr: Multivitamin and Mineral Supplements Reduce Lung Cancer Risk in Older People!
Time of Update: 2022-04-23
Compared with placebo, routine daily MVM supplementation reduced lung cancer risk in older adults, but not overall cancer risk and had no significant effect on cardiovascular disease risk .
-
Front Oncol: Systematic lymphadenectomy improves patient outcomes in patients with early-stage endometrial clear cell carcinoma
Time of Update: 2022-04-23
Studies have shown that patients with early-stage endometrial clear cell carcinoma who underwent systematic lymphadenectomy had better long-term survival than those who did not .
Studies have shown that patients with early-stage endometrial clear cell carcinoma who underwent systematic lymphadenectomy had better long-term survival than those who did not .
-
FDA Eligibility Criteria for Cancer Clinical Trials: Available Therapies in Nontherapeutic Settings (Draft)
Time of Update: 2022-04-23
S. Food and Drug Administration (FDA, Food and Drug Administration)Release date: 2022-03-14release date:brief introduction:brief introduction:This guidance provides recommendations for clinical investigators and sponsors regarding the inclusion of patients who have not received available treatments for their cancer (often referred to as existing treatment options) into clinical trials of non-curative cancer treatments and biologics .
-
For every additional 10 μg/day, colorectal risk decreased by 8%!
Time of Update: 2022-04-23
The estimated effect of dietary selenium intake (ie, every 10 μg increase per day) was associated with a 10–6% decrease in odds ratios, depending on the number of covariates considered (Table 2) .
-
Zhang Feng's new paper: CRISPR activation screening to discover key proteins of cancer immunotherapy resistance
Time of Update: 2022-04-23
The study found that BCL-2 and B3GNT2 are key drivers of cancer cell resistance to cytotoxic T cells through CRISPRa Screen, and inhibition of these two proteins can enhance the sensitivity of tumor tissue to immunotherapyThis result suggests that a CRISPR-activated screening system can help to elucidate resistance pathways and identify potential targets for cancer immunotherapy .
-
"Cold tumor" becomes "hot tumor"!
Time of Update: 2022-04-23
This study revealed the molecular mechanism by which inhibition of deubiquitinating enzyme USP8 remodels the tumor immune microenvironment (TME), turning "cold tumors" into "hot tumors", thereby improving the effect of tumor immunotherapy .
-
Cell: Natural antibodies exist in cancer patients' tumors, opening up new directions for cancer treatment
Time of Update: 2022-04-23
Cell Tumor-reactive antibodies evolve from non-binding and autoreactive precursorsThe study confirms that B lymphocytes of cancer patients can produce natural antibodies that specifically target the tumor, paving the way for a new tumor immunotherapy that promises to use this different and never before used weapon of the immune system - natural antibodies .
-
JAMA Oncol: The longer you are overweight, the higher your risk of colorectal cancer!
Time of Update: 2022-04-23
54 WYO increases by 5% for each SD value of CRC riskThe results of this study suggest that the effect of long-term overweight on colorectal cancer risk is significantly higher than that estimated based on BMI measurements at a single time point .
-
J Immunother Cancer: Efficacy and safety of camrelizumab plus chemotherapy as preoperative adjuvant therapy for locally advanced esophageal cancer
Time of Update: 2022-04-23
Robust antitumor activity of camrelizumab in combination with chemotherapy in locally advanced esophageal squamous cell carcinoma without unexpected safety concerns .
Robust antitumor activity of camrelizumab in combination with chemotherapy in locally advanced esophageal squamous cell carcinoma without unexpected safety concerns Original source:Original source:Liu Jun,Yang Yang,Liu Zhichao et al.
-
Eur J Cancer: Letrozole + Palbociclib Neoadjuvant Therapy May Replace Chemotherapy for High-Risk ER+HER2- Breast Cancer
Time of Update: 2022-04-23
In conclusion, the NEOPAL study shows that the letrozole-palbociclib neoadjuvant therapy regimen is expected to save some patients with intraluminal breast cancer from the pain of chemotherapy, and at the same time obtain a better long-term prognosis .
-
Oncologist: BRAF mutation is associated with poor prognosis in mismatch repair deletion (MMR-D)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-22
In conclusion, the study showed that in patients with mismatch repair gene deletion (MMR-D) metastatic colorectal cancer (mCRC), BRAF mutation and age >50 years were associated with poor prognosis, and immunotherapy could improve the prognosis of patients .
-
Thorac Cancer: ALK positivity is a negative predictor of recurrence-free survival (RFS) in patients with stage I completely resected lung adenocarcinoma
Time of Update: 2022-04-22
Recently, Thoracic Cancer published a study to evaluate the prognostic and predictive significance of ALK positivity in patients with completely resected lung adenocarcinoma .
Recently, Thoracic Cancer published a study to evaluate the prognostic and predictive significance of ALK positivity in patients with completely resected lung adenocarcinoma .
-
11,100 people are diagnosed with cancer every day!
Time of Update: 2022-04-22
(A) Cancer incidence and new cases by sex and age; (B) Cancer mortality by age and mortality by sex Lung, liver, stomach, colorectal, and esophageal cancers were the five causes of cancer deaths, accounting for 69.
-
Immunity: Yogurt is not harmless!
Time of Update: 2022-04-22
A new study shows that lactic acid bacteria, a type of bacteria thought to promote gut health, can promote tumor growth by affecting the metabolism of tryptophan and thus the function of macrophages .
We examined the effect of AHR (aryl hydrocarbon receptor) on associated macrophage (TAM) function in pancreatic ductal adenocarcinoma (PDAC) .
-
Spider silk enhances the anticancer ability of p53 and is expected to develop a broad-spectrum mRNA cancer vaccine
Time of Update: 2022-04-22
In this study, the p53 protein was fused to the N -terminal domain of the native highly stable spider silk protein to construct a highly expressed and more structurally stable fusion p53 protein, which has full physiological activity in human cancer cells .
-
Brit J Cancer: Microbial markers for predicting colorectal tumor risk
Time of Update: 2022-04-22
DigestionThus, this review provides evidence supporting the association between different types of microbial species and their perspective on their predictive value for colorectal tumors .
This review provides evidence supporting the association between different types of microbial species and their predictive value for colorectal tumors .
-
BMC Cancer: The Zhongzhun team has a remarkable curative effect on the transformation model therapy for HER2-positive refractory metastatic breast cancer
Time of Update: 2022-04-22
The study included patients with rapidly progressive HER2-positive metastatic breast cancer treated with trastuzumab in 6 hospitals in China who switched to oral lapatinib 1250 mg qd + capecitabine (1000 mg/m2 bid d1-d14 per day) or vinorelbine Bing (25 mg/m2/time, intravenous injection, d1 and d8, every 21 days as a cycle) .